U.S. Pharmacist eNewsletter
September 2022

FDA Authorizes EUAs for Bivalent COVID-19 Vaccine Boosters

On August 31, 2022, the FDA amended the Emergency Use Authorization (EUA) of both the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least 2 months following primary or booster vaccination. Learn more about these vaccines and what the FDA has to say about them.


COVID-19 Vaccines Safe in Patients With Heart Failure
According to a poster presentation at the European Society of Cardiology Congress 2022, COVID-19 mRNA vaccines are correlated with a diminished risk of death in patients with heart failure (HF), and the vaccines were not associated with an increased risk of worsening HF, venous thromboembolism, or myocarditis in HF patients. Learn more about the results of this study.

COVID-19 Vaccine and Booster Use in Patients With Lupus
According to data collected during the Omicron BA.1 wave in New York and published in The Lancet Rheumatology, patients with systemic lupus erythematous (SLE) achieved an enhanced serological response following a COVID-19 vaccine booster dose. The new study tracked the health of fully vaccinated men and women being treated for SLE at its affiliated hospitals in New York City. Read more.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App